Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04399356 · ClinicalTrials.gov registry record · Phase 2
Niclosamide for Mild to Moderate COVID-19
A Phase 2 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT04399356 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 73 participants.
The verdict
NCT04399356, a Phase 2 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
Interventions
- DRUG Placebo
- DRUG Niclosamide
- OTHER Telehealth monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2021-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04399356
The ClinicalTrials.gov registry entry for NCT04399356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04399356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04399356 about?
NCT04399356 is a clinical study titled "Niclosamide for Mild to Moderate COVID-19". This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04399356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2020-10-01. Estimated completion is 2021-08-19.
What interventions are being tested in trial NCT04399356?
The interventions under investigation include: Placebo (DRUG), Niclosamide (DRUG), Telehealth monitoring (OTHER).
Who is sponsoring clinical trial NCT04399356?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.